NCT03977350

Brief Summary

Cognitive complications after major surgery are a common phenomenon. The incidence of Postoperative Cognitive Dysfunction (POCD), may vary from 5% to 25% in adult patients, depending on different risk factors. Age has been strongly associated with cognitive complications. POCD is a prolonged decline in cognitive function that appears after surgery as compared with preoperative functions. In order to classify evaluate POCD, it requires at least 2 measurements. A baseline, completed before surgery and a second measurement, post surgery. In light of the high prevalence of POCD and the difficulties in its prediction, NeuroIndex has developed a quantitative EEG system and software that aim to produces risk predictor index (IS) for POCD. This study aims to evaluate the relationship between the software produced predictor index and the actual POCD events. The qEEG will be monitored during the surgery in addition to the routine clinical practice in operating rooms. POCD will be evaluated using Montreal Cognitive Assessment test (MoCA) prior and post surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 4, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 6, 2019

Completed
4 months until next milestone

Study Start

First participant enrolled

September 23, 2019

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2021

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

September 11, 2020

Status Verified

September 1, 2020

Enrollment Period

1.9 years

First QC Date

June 4, 2019

Last Update Submit

September 9, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • The qEEG parameter IS correlation with POCD

    The qEEG parameter IS, which range between 0 and 1, where higher scores are more favorable than lower scores will be evaluated for its correlation with POCD that will be measured by Montreal Cognitive Assessment (MoCA)

    1 week following surgery

Study Arms (1)

Patients over 65 years undergoing heart surgery

Patients over 65 years undergoing heart surgery under anesthesia, EEG monitored

Device: EEG monitoring

Interventions

EEG monitoring under general anesthesia

Patients over 65 years undergoing heart surgery

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)
Sampling MethodProbability Sample
Study Population

The study population will consist of male and female adults undergoing cardiac surgery under general anesthesia

You may qualify if:

  • Males and females between the ages of 65 or above.
  • Subjects with American Society of Anesthesiologists physical status I-III.
  • Subjects who are intended to undergo cardiac surgery (CABG or valve replacement) under general anesthesia.
  • Surgical procedures scheduled for over 30 minutes.
  • Lack of significant hearing disturbances.
  • Subjects with ability to read and understand the consent form.

You may not qualify if:

  • Significant visual impairment so that the pictures of the confusion assessment method could not be interpreted to accurately test to assess delirium.
  • Profound dementia or aphasia that interfered with the assessment of cognitive dysfunction (positive delirium in CAM-ICU).
  • Patients with a history of stroke.
  • Any documented major neurologic or psychiatric dysfunction.
  • Pregnant women.
  • Long term use of sedative-hypnotic drugs and antidepressant drug.
  • Subjects with scalp or skull abnormalities (s/p brain surgery, cranial implants).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Carmel Medical Center

Haifa, 3436212, Israel

RECRUITING

MeSH Terms

Conditions

Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental Disorders

Study Officials

  • Dror Leviner, Dr.

    Carmel Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ester Pri-Or, Nurse CRA

CONTACT

Tamar A Arens, Dr.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 4, 2019

First Posted

June 6, 2019

Study Start

September 23, 2019

Primary Completion

September 1, 2021

Study Completion

December 1, 2022

Last Updated

September 11, 2020

Record last verified: 2020-09

Data Sharing

IPD Sharing
Will not share

Locations